HDAC7
HDAC7 (histone deacetylase 7) is a class IIa histone deacetylase that functions as a signal-responsive transcriptional coregulator linking extracellular stimuli to chromatin-dependent gene regulation and cell fate control[1][2]. HDAC7 undergoes regulated nucleo-cytoplasmic shuttling through phosphorylation-dependent mechanisms, allowing it to integrate signaling pathways with transcriptional programs that govern development, immunity, and vascular biology[1][3]. Mechanistically, HDAC7 participates in the control of endothelial growth, migration, angiogenesis, and vascular integrity, and VEGF-dependent signaling can promote HDAC7 phosphorylation and redistribution to regulate endothelial responses[3][4][5]. In disease-associated contexts, aberrant HDAC7 expression has been linked to tumor progression, metastasis, vascular microenvironment remodeling, and therapeutic resistance, supporting its relevance as a candidate biomarker and experimental target in cancer research[6]. Compared with related class IIa isoforms, including HDAC4, HDAC5, and HDAC9, HDAC7 is distinguished by its prominent role as a signaling hub that couples cellular localization dynamics with transcriptional regulation in endothelial and immune systems[1][2]. Furthermore, class IIa HDACs possess relatively low intrinsic deacetylase activity and frequently function through protein-protein interactions and corepressor complexes; HDAC7 has been reported to associate with HDAC3, highlighting a mechanistic distinction from catalytically active class I HDACs[7]. For experimental applications, HDAC-targeting compounds such as vorinostat affect HDAC7 among other HDAC family members, and ongoing efforts to improve isoform selectivity continue to inform the design of epigenetic and cancer-focused research strategies[6][8].
References:
- [1]. Atochin DN, et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest. 2007 Jul;117(7):1961-7. [Content Brief]
- [2]. Margariti A, et al. Histone deacetylase 7 controls endothelial cell growth through modulation of beta-catenin. Circ Res. 2010 Apr 16;106(7):1202-11. [Content Brief]
- [3]. Yin X, et al. Multiple red blood cell flows through microvascular bifurcations: cell free layer, cell trajectory, and hematocrit separation. Microvasc Res. 2013 Sep;89:47-56. [Content Brief]
- [4]. Liu C, et al. HDAC7: a promising target in cancer. Front Oncol. 2024 Feb 28;14:1327933. [Content Brief]
- [5]. Rabezanahary H, et al. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada. Heliyon. 2024 May 21;10(10):e31026. [Content Brief]
All Product Categories
-
HDAC7 Related Products (53)
Related Products (53)
-
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
![Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside](https://file.medchemexpress.com/product_pic/hy-n5084.gif "Click to View Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside Product Detail")
0 ImagesPinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
-
Bavarostat
0 ImagesSynonyms: EKZ-001Bavarostat (EKZ-001) is a blood-brain barrier-permeable, potent HDAC6 inhibitor and PET radiotracer, with an IC50 as low as 17 nM against human HDAC6. Bavarostat can be labeled with 18F and used as a probe to map HDAC6 distribution and measure target occupancy in the brains of non-human primates. Bavarostat also selectively modulates tubulin acetylation, but not histone acetylation. Bavarostat is applicable for research on Alzheimer's disease, other neurodegenerative disorders, and cancers.
-
HDAC-IN-53
0 ImagesCat. No.: HY-149208CAS No.: 2921948-27-6HDAC-IN-53 is an orally active, and selective HDAC1-3 inhibitor with IC50 values of 47 nM, 125 nM, and 450 nM, respectively. HDAC-IN-53 does not inhibit class II HDACs (HDAC4, 5, 6, 7, 9; IC50>10 μM). HDAC-IN-53 induces caspase-dependent apoptosis. HDAC-IN-53 significantly inhibits the growth of human tumor xenografts in nude mice and murine tumor growth in immune-competent mice bearing MC38 colon cancer.
-
XSJ-10
0 ImagesCat. No.: HY-157740XSJ-10 is a HDAC inhibitor containing a RAS/RAF protein interfering unit, with IC50s of 0.05 and 0.04 μM in PANC-1 cells and HT-29 cells. XSJ-10 can effectively induce the apoptosis of cancer cells and suppress the tumor by strongly inhibiting the RAS-RAF-MEK-ERK signaling pathway and the acetylation level of HDAC3.
-
HDAC6-IN-5
0 ImagesCat. No.: HY-146678CAS No.: 2413603-15-1HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM. HDAC6-IN-5 exhibits strong inhibitory activity against Aβ1-42 self-aggregation and AChE, with IC50 values of 3.0 and 0.72 μM. HDAC6-IN-5 can enhance neurite outgrowth without significant neurotoxicity.
-
HDAC6-IN-6
0 ImagesCat. No.: HY-146679CAS No.: 2413603-10-6HDAC6-IN-6 (compound 6a) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM. HDAC6-IN-6 exhibits strong inhibitory activity against Aβ1-42 self-aggregation and AChE, with IC50 values of 3.0 and 0.72 μM. HDAC6-IN-6 can enhance neurite outgrowth without significant neurotoxicity.
-
Tubulin/HDAC-IN-4
0 ImagesCat. No.: HY-162319Tubulin/HDAC-IN-4 (compound 9n) is a dual Tubulin and HDAC inhibitor with IC50 values of 0.73, 0.43, 0.62, 2.34 µM for HDAC1, HDAC2, HDAC6, HDAC7, respectively. Tubulin/HDAC-IN-4 inhibits the tubulin polymerization by targeting the colchicine binding site. Tubulin/HDAC-IN-4 induces apoptosis and cell cycle arrest at G2/M phase. Tubulin/HDAC-IN-4 induces a significant elevation of intracellular ROS levels. Tubulin/HDAC-IN-4 shows anti-angiogenesis activity and anticancer activity.
-
HDAC-IN-36
0 ImagesCat. No.: HY-146684CAS No.: 2482992-54-9
-
TNI-97
0 ImagesCat. No.: HY-175030CAS No.: 2790425-52-2TNI-97 is a selective and orally active HDAC6 inhibitor, with an IC50 of 0.2 nM. TNI-97 potently inhibited TNBC cell MDA-MB-453 growth and clonogenicity. TNI-97 induces PANoptosis including apoptosis, necroptosis and pyroptosis in MDA-MB-453 cells. TNI-97 shows antitumor activity in the mice carrying the MDA-MB-453 xenograft or carrying murine-derived TNBC cell allografts. TNI-97 can be used for the study of triple-negative breast cancer.
-
HDAC3-IN-4
0 ImagesCat. No.: HY-159172CAS No.: 2988762-46-3
-
HDAC6-IN-10
0 ImagesCat. No.: HY-150595CAS No.: 2408286-73-5HDAC6-IN-10 is a highly selective HDAC6 inhibitor with the IC50 of 0.73 nM. HDAC6-IN-10 has 144~10941-fold selectivity over other HDAC isoforms. HDAC6-IN-10 shows anti-proliferative activities against multiple myeloma cells.
-
ALK/HDAC-IN-2
0 ImagesCat. No.: HY-180811ALK/HDAC-IN-2 (Compound 19b) is an ALK/HDAC inhibitor with IC₅₀ values for ALK WT and total HDACs of 8 nM and 1.18 μM, respectively. ALK/HDAC-IN-2 exhibits inhibitory activity against ALK mutants G1202R, F1174L, and L1196M, with IC₅₀ values of 2.74, 9.23, and 34.28 nM, respectively. ALK/HDAC-IN-2 shows potent and selective inhibition against HDAC1 (IC₅₀ = 0.24 μM), while its inhibitory activity against HDAC7, HDAC6, and HDAC11 is weak (IC₅₀ > 10 μM). ALK/HDAC-IN-2 has broad-spectrum anti-proliferative activity against various cancer cells, inducing cell cycle arrest and apoptosis. ALK/HDAC-IN-2 can be used for the study of neuroblastoma.
-
MC2590
0 ImagesMC2590 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2590 is a inhibitor of HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC50s of 0.015 μM-0.156 μM. MC2590 also inhibits HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with IC50s of 1.35 μM-3.98 μM. MC2625 induces G2/M cell cycle arrest and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction.
